New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
Presented by R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Emory University and Winship Cancer Institute, Atlanta, Georgia
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2018;9(3):282–286 |
© 2018 Harborside™
FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized.
For access to the full length article, please sign in